This site is intended for healthcare professionals only
LoginRegister
Cipla, Kemwell Ink Joint Venture Pact to Boost Global Biologics PlayCipla (EU), UK incorporates new wholly owned subsidiary in Germany
Illegally marketed formulations under name of Biovus Pharma seized at MoosarambaghIllegally marketed formulations under name of Biovus Pharma seized at Moosarambagh
HRV Pharma, SMS LifeSciences Partner to Scale Orphan and Specialty APIsFresenius Told To Submit Approval Basis, Phase III Data for Calcium Chloride Dihydrate Infusion...
Novartis to Acquire Excellergy in USD 2 Billion Deal to Boost Food Allergy PipelineCDSCO Panel Asks Novartis to Submit Revised Protocol, Dose Changes for Ianalumab Phase III Trial
Sanofi DupixentItepekimab met primary endpoint in one of two COPD phase 3 studies: Sanofi, Regeneron
Amazon Only a Platform, Not Seller of Abortion Pills: Court Quashes Notice Against DirectorsASCI Flags 233 Health Ads for DMR Act Violation, Reports to AYUSH Ministry
Strides Pharma Science: Nandini Matiyani joins as Executive VP - Human ResourcesStrides Pharma Science: Senior Vice President - Treasury Ramesh RJ supperannuates
Cipla, Hetero win bid to supply widely prescribed diabetes drug in ChinaDon't throw in the bin, please flush it! CDSCO dictum for these 17 medicines
Delhi HC Bars Dr Reddys from Selling Olymviq Over Similarity with Novo Nordisks OzempicDelhi HC Restrains Dr Reddy's from Selling Semaglutide Drug in India Amid Novo Nordisk Row
CDSCO Clears AstraZenecas Imfinzi (Durvalumab) for Additional Cancer Indication in IndiaJustify Sample Size Hike in FDC Trial of Zibotentan-Dapagliflozin, CDSCO Panel Tells AstraZeneca
Bayer-Regeneron Aflibercept 8 mg recommended for EU approval for third retinal indicationBayer Gets CDSCO Panel Nod To Conduct Phase 3 Trial for Finerenone
Mercks Enlicitide Outperforms Rivals in Cutting Bad Cholesterol in Late-Stage TrialMerck, Daiichi Sankyo withdraw US appication for patritumab deruxtecan for advanced or metastatic...
X